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Highlights 
  
● Parkinson’s patients were more active between 8am and 1pm; 
● Patients summed 72±39 (mean±standard deviation) minutes of walking per day.  
● The severity of motor fluctuations did not correlate with time spent walking. 
● Higher age and greater disease severity correlated with less time spent walking. 
● The severity of motor fluctuations did not impact time spent walking after levodopa. 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
Abstract 
  
Background: people with PD (PWP) have an increased risk of becoming inactive. Wearable sensors 
can provide insights into daily physical activity and walking patterns. 
Research questions: (1) is the severity of motor fluctuations associated with sensor-derived average 
daily walking quantity? (2) is the severity of motor fluctuations associated with the amount of 
change in sensor-derived walking quantity after levodopa intake? 
Methods: 304 Dutch PWP from the Parkinson@Home study were included. At baseline, all 
participants received a clinical examination. During the follow-up period (median: 97 days; 25-
Interquartile range-IQR: 91 days, 75-IQR: 188 days), participants used the Fox Wearable Companion 
app and streamed smartwatch accelerometer data to a cloud platform. The first research question 
was assessed by linear regression on the sensor-derived mean time spent walking/day with the 
severity of fluctuations (MDS-UPDRS item 4.4) as independent variable, controlled for age and MDS-
UPDRS part-III score. The second research question was assessed by linear regression on the sensor-
derived mean post-levodopa walking quantity, with the sensor-derived mean pre-levodopa walking 
quantity and severity of fluctuations as independent variables, controlled for mean time spent 
walking per day, age and MDS-UPDRS part-III score.  
Results: PWP spent most time walking between 8am and 1pm, summing up to 72±39 
(mean±standard deviation) minutes of walking/day. The severity of motor fluctuations did not 
influence the mean time spent walking (B=2.4±1.9, p=0.20), but higher age (B=-1.3±0.3, p=<0.001) 
and greater severity of motor symptoms (B=-0.6±0.2, p<0.001) was associated with less time spent 
walking (F(3,216) = 14.6, p<.001, R2 =.17). The severity of fluctuations was not associated with the 
amount of change in time spent walking in relation to levodopa intake in any part of the day.  
Significance: Analysis of sensor-derived gait quantity suggests that the severity of motor fluctuations 
is not associated with changes in real-life walking patterns in mildly to moderate affected PWP. 
  
Keywords: Parkinson’s disease; Ambulatory monitoring; Gait quantity; Wearable devices; Motor 
fluctuations 
 
 
 
 
 1. Introduction 
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People with Parkinson’s disease (PWP) are at risk of developing an inactive lifestyle[1]. The reason 
for this is multifactorial, with involvement of both physical and psychological factors. Some of these 
risk factors are non-specific, such as older age and fear of falling[2, 3], while others are more specific 
to PD, such as reduced physical capacity or gait and balance problems[4, 5]. Being physically inactive 
is generally undesirable, particularly for PWP. Traditionally, self-reported diaries and questionnaires 
are used to assess daily physical activity. These instruments have dubious reliability and validity, in 
particular for people with cognitive impairments[6]. To overcome limitations related to self-reported 
activity, wearable sensors may provide more objective and continuous measurements, with the 
potential to generate novel insights into real-life activity patterns in PWP. Early studies that used 
wearable sensors to quantify physical activity in PD showed that greater disease severity correlates 
with less ambulatory activity[2, 7, 8]. These studies typically had small sample sizes, with the 
exception of one (n=586)[2], and had short follow-up periods (maximum 7 days). 
  
In addition to assessing the overall amount of ambulatory activity, wearable sensors offer the 
possibility to study activity patterns throughout the day in detail. This is particularly relevant for PWP 
who experience motor fluctuations, i.e. periods with either a good levodopa therapy response (“ON” 
state) or periods when the medication effects wear off and motor symptoms re-emerge (“OFF” 
state)[9]. The presence of OFF periods has a large limiting impact on mobility and quality of life in 
PD[10, 11]. It is known that gait patterns change in response to levodopa intake in PWP with motor 
fluctuations [12] and small-scale studies demonstrated that wearable sensors can capture the effects 
of levodopa on gait quality[13-15]. However, the impact of levodopa intake on gait quantity, as a 
measure of physical activity, is largely unknown and has never been studied in a large population 
followed for a long period of time. 
  
Therefore, the aim of this study is to investigate whether the severity of motor fluctuations is 
associated with changes in physical activity patterns in a large cohort of PWP, who used wearable 
sensors for a prolonged period of time (up to 665 days). As walking is the most common activity for 
older adults, the mean time spent walking in minutes per day – labeled as “gait quantity” in this 
study – is used as a proxy measure of physical activity. 
  
 
 
 
2. Methodology 
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2.1 Participants 
Patients included in this study participated in the Dutch cohort of the Parkinson@Home study. The 
Parkinson@Home study was an observational, two-cohort (North America and The Netherlands) 
study aiming to investigate the feasibility of large-scale deployment and the compliance with 
wearable sensor usage over a long follow-up time. The recruitment process and study design were 
previously described in detail[16]. In summary, in the Dutch cohort, 304 participants were recruited 
from support groups, internet communities, and through physiotherapists specialized in treating 
PWP. Inclusion criteria were: 30 years of age or older; possession of a smartphone with Android OS 
version ≥ 4.2; and self-reported diagnosis of PD. No exclusion criteria were applied. Participants used 
the Fox Wearable Companion app developed by Intel® Pharma Analytics Platform team[17]. The 
application was installed on the participants own Android smartphone and on a Pebble smartwatch 
provided by the research team. Participants were asked to wear the smartwatch and keep their 
smartphone with them as much as possible on a 24/7 basis for 13-weeks. At the end of the 13-weeks 
study period, participants had the option to continue using the system, if they wished. The 
Parkinson@Home study showed that compliance of PWP with the wearable system was high[16]. 
  
This study was conducted in compliance with the Ethical Principles for Medical Research Involving 
Human Subjects, as defined in the Declaration of Helsinki. The study protocol was approved by the 
local ethics committee (CMO Arnhem-Nijmegen; NL53034.091.15). 
  
2.2 Data collection 
Data used in this study were collected during the Parkinson@Home study and obtained from a 
database curated by the Michael J. Fox Foundation. The Fox Wearable Companion app platform 
used in that study enables raw smartwatch accelerometer data capture (average 50 Hz sampling 
rate) streaming via Bluetooth radio to a complementary smartphone Android  app. Next, the 
smartphone app transfers data via Wi-Fi or mobile data to the Intel® Pharma Analytics cloud 
platform, which uses machine learning to estimate objective measures of participants behavior. 
Among these objective measures is a gait detection algorithm, which estimates whether or not a 
person was walking during a specific time interval. For the detection of gait episodes, an algorithm 
was trained on 10 hours of walking and non-walking episodes collected from PD (N=19) and non PD 
(N=12) participants wearing a smartwatch. Raw accelerometer data were segmented into 5 second 
interval and transformed into aggregate features in the time and frequency domains. Then, a 
decision tree model was used to classify every 5-second interval as either walking or non-walking. 
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The algorithm accuracy was 98.5% (precision 98.9%, recall 96%) on the training data[17] (see 
Appendix  A for algorithm details). The objective measures are presented to participants using 
graphs and summary reports within the app. In addition to using the smartwatch and smartphone 
app, users were asked to set medication reminders and report their daily actual medication intake 
within the app (Figure 1). Finally, all enrolled participants received a single medical examination, 
based on the “Parkinson's Progression Markers Initiative” (PPMI) protocol. The medical examination 
collected information such as time since diagnosis and the full MDS-UPDRS[18]. The medical 
examination was performed in the ON state by specially trained physiotherapists who are members 
of ParkinsonNet, a Dutch network of health professionals specialized in PD management. 
  
2.3 Outcomes and statistical analysis 
 
Two statistical analyses were performed. The first analysis aimed to assess whether a higher severity 
of motor fluctuations is associated with a smaller mean time spent walking per day. Only 
participants that contributed at least 7 days of accelerometer data during the follow-up period were 
included. The mean time spent walking per day was calculated by first dividing the total number of 
minutes identified as walking by the total number of minutes of accelerometer data. Next, this ratio 
was multiplied by 1440, i.e. the number of minutes in a day, to obtain the daily mean expressed in 
minutes. The severity of fluctuations was determined by the score of item 4.4 of the MDS-UPDRS 
Part IV (question: “4.4 Functional impact of fluctuations”) and the severity of motor symptoms was 
expressed as the sum score of the MDS-UPDRS Part III. Both outcomes were treated as scale 
variables in the analyses. Linear regression analysis was performed on the mean time spent walking 
per day, with the severity of fluctuations as independent variable. To control for potential 
confounders, age and MDS-UPDRS part III scores were included in the model using a backward 
stepwise input selection (criterion of removal: probability of F>0.10). 
  
The second analysis aimed to investigate whether a higher severity of motor fluctuations is 
associated with a higher change in time spent walking after levodopa intake. Only levodopa intakes 
were considered because this drug has the strongest association with occurrence of fluctuations[19]. 
The analysis was performed separately for the morning (between 6:00 and 12:00), afternoon 
(between 12:00 and 18:00), evening (between 18:00 and 0:00) and night (between 0:00 and 6:00), 
because both the amount of walking[20] and the responsiveness to levodopa may vary across the 
day[21]. To account for possible participants errors while reporting medication intake, e.g. reporting 
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the same medication intake time point multiple times, only the first report within a certain hour was 
considered as the actual time of medication intake. 
  
To assess the change in time spent walking, we calculated both the mean time spent walking in the 
second hour after levodopa intake (post-levodopa activity) and the mean time spent walking in the 
last hour before levodopa intake (pre-levodopa activity) per individual (Figure 2). Only pairs of pre-
levodopa and post-levodopa activity consisting of at least 115 minutes of data, out of a possible total 
of 120 minutes during those two hours, were included. Moreover, participants needed to have at 
least a total of 10 unique levodopa reports in the part of the day being analyzed. Linear regression 
was performed on the mean post-levodopa activity, with the mean pre-levodopa activity and the 
severity of fluctuations as independent variables. To control for potential confounders, the mean 
time spent walking per day, age and MDS-UPDRS part III score were included as inputs to the model 
using  backward stepwise selection (criterion of removal: probability of F>0.10). 
 
For the coefficients, a critical p-value of 0.05 was applied. All analyses were performed using the 
Statistical Package for the Social Sciences (SPSS®) Version 22. 
  
3. Results 
The cohort consisted of 304 mostly mildly to moderately affected PWP (Table 1).  
 
3.1 Impact of motor fluctuations on daily time spent walking 
220 participants were included in analysis 1. They contributed a median of 78 complete days of 
usable accelerometer data (25 Interquartile range-IQR: 60 days, 75 Interquartile range-IQR: 110 
days), during a median of 97 days of follow-up period (25-IQR of 91 days and 75-IQR of 188 days). On 
average, participants walked 72±39 minutes per day, with the largest number of minutes walked 
occurring between 8 am and 1 pm (Figure 3). The severity of motor fluctuations did not influence the 
mean time spent walking (B=2.4±1.9, p=0.20), whereas higher age (B=-1.3±0.3, p=<0.001) and higher 
severity of motor symptoms (B=-0.6±0.2, p<0.001) was associated with  less time spent walking 
(model F(3,216) = 14.6, p<.001, R2 = .17). 
 
3.2 Impact of fluctuations on the change in time spent walking after levodopa intake 
The post-levodopa activity was on average higher than the pre-levodopa activity in the morning and 
night, while in the afternoon and evening the post-levodopa activity was lower. The pattern of post-
levodopa activity did not differ between week or weekend days (Figure 4a/b). The severity of 
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fluctuations was not significantly associated with the difference between pre- and post-levodopa 
activity (i.e. the amount of change in walking quantity) in any part of the day (Table 2).  
4. Discussion 
 
This study presents data from the first large-scale cohort study using wrist-worn accelerometry in 
which  sensor-based passive monitoring was combined with daily reports of levodopa intake. The 
much longer follow-up time here (up to 665 days, with a median follow-up of 97 days) contrasts 
markedly with previous studies using wearable sensors, where follow-up was typically limited to one 
week[8, 13, 22, 23]. Our sample size was also large. Using this sizeable dataset, we demonstrated 
that the severity of motor fluctuations did not lead to a smaller mean amount of daily walking 
quantity. Also, higher severity of motor fluctuations did not  cause a higher mean change in walking 
quantity in relation to levodopa intake. These findings contradict our hypothesis that PWP with more 
severe motor fluctuations would be more inactive before intake of levodopa, as a result of wearing 
off. Studies in controlled settings showed that motor performance, which includes gait and postural 
transitions, is worse during off periods[12]. Thus, it seems reasonable that this could affect the 
amount of real-life walking quantity, both through physical limitations and through a patient’s 
confidence in being active. Therefore, a careful interpretation of possible explanations for our 
present results is needed. 
  
Our findings highlight the complexity of studying physical activity in a free-living environment, where 
little or no contextual information about participants behavior is known. As a reflection of this, large 
variation in the amount of activity is present both between patients and within patients on different 
days. Our study showed that the severity of potential fluctuations around the time of levodopa 
intake does not explain a substantial proportion of this already large variation in walking quantity. 
On the one hand, this may be explained by the fact that a patient’s activity pattern is highly 
influenced by behavioral factors that are not related to the severity of symptoms. For example, the 
influence of participants’ behavior most likely explains the large increase in the time spent walking 
after levodopa intake during the night presented in Figure 4. As the majority of the levodopa reports 
at night took place around 5 a.m., the comparison includes a part of the morning, with a higher 
number of minutes walked. On the other hand, our results indicate that the severity of fluctuations 
does not have a detectable or consistent influence on activities around the time of levodopa intake. 
This is supported by the fact that patients in our study were on average still active before levodopa 
administration, regardless of the severity of their fluctuations. It should be emphasized that we 
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investigated a relatively mildly to moderately affected PD population, hence the generalizability to 
later stage PWP, who typically have more disabling fluctuations[24], remains to be addressed.  
  
Some limitations of this approach need to be discussed. First, the severity of fluctuations was based 
on item 4.4 from the MDS-UPDRS part IV, which may be susceptible to inter-rater variability. 
However, it is a valid scale[25] and all assessors involved in this study received additional training for 
conducting the MDS-UPDRS. Using alternative approaches to evaluate motor fluctuations, such as 
the Hauser dairy [26], might allow for a more accurate comparison of the amount of activity 
between OFF and ON periods, particularly if fluctuations are characterized by unpredictable OFF 
periods, dose failures or delayed ON periods. However, it is unlikely that these phenomena were 
important in our study sample, as these typically occur in people with more advanced PD [27]. 
Second, limitations related to compliance may have influenced the results. Because data related to 
actual wear time were not available, we cannot guarantee that all sensor data were collected while 
the participants were in fact wearing the smartwatch. To minimize this risk and filter out highly non-
compliant participants, we have only including participants with a minimum amount of streamed 
data. In addition, we have no reason to believe that the proportion of non-wear data correlates with 
our main variable of interest, namely the severity of fluctuations. Although the gait detection 
algorithm was only validated in a lab-based setting [17], the outcomes of both the mean walking 
quantity and the daily pattern are similar to what has been reported earlier [2, 20, 28]. Moreover, 
we were also able to reproduce earlier findings that age and MDS-UPDRS part III are determinants 
for the amount of activity[1, 8]. These findings give us some confidence that the gait measurements 
from the smartwatch data are reasonably reliable. Lastly, although we have no data on the accuracy 
or compliance with medication reports through the app, we believe that the medication reminders 
and the high compliance with the system usage increased the accuracy of medication reports. 
Despite the fact that our findings contradict those of a small study with a short follow-up [29], we 
posit  that limitations in their data analysis (e.g. only comparing post- and pre-levodopa activity 
without assessing the influence of the severity/presence of fluctuations on this difference, producing 
a result that is highly influenced by general behavioral factors) explain the divergence in conclusions. 
  
A clinically relevant conclusion of our findings is that gait quantity is not a suitable way to capture 
wearing off in mild to moderately affected PWP. Instead, the use of gait quality features that are 
more responsive to levodopa[9], reflect changes over time[30], and are likely less affected by 
behavior, appears as a more adequate approach to monitor changes in gait due to motor 
fluctuations in a real-life environment. Together with the role of gait quality analysis, determining 
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optimal sensor type, sensor location and feature extraction for home-based monitoring still remains 
to be addressed. Lastly, in addition to exploring the role of gait quality to capture the influence of 
fluctuations on walking patterns, future research into activity patterns of PWP would benefit from a 
more heterogeneous PWP group and age-matched healthy controls, to be able to better 
discriminate between PD-specific and behavioral influences in activity patterns. Hopefully, this will 
lead to a better understanding of the underlying factors that have an impact on physical activity in 
PD, and generate useful knowledge that can further contribute to the promotion of an active life-
style among PWP. 
  
In conclusion, this study showed that the severity of motor fluctuations was not associated with the 
mean amount of walking quantity in PWP. Similarly, the severity of motor fluctuations was not 
associated with  the mean change in walking quantity in relation to levodopa intake. Finally, our 
study does not support the assessment of  gait quantity as a suitable method to investigate the 
influence of motor fluctuations on walking activity in real-life.    
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Figure 1: screenshots of the Fox Wearable Companion app: (A) main screen; (B) activity graph; (C) 
movement during sleep graph; (D) medication reminder. 
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Figure 2: Data reduction and pre/post-levodopa activity calculation per participant. 
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Figure 3: Mean time spent walking during each hour of the day (n=220). Error bars indicate standard 
error of the mean. 
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 Figure 4: 4A - Mean time spent walking per hour before (black) and after levodopa intake (white) on 
week days, presented separately for the morning (n=182, number of levodopa reports per person 
ranging from 11 to 429), afternoon (n=175, number of levodopa reports ranging from 11 to 323), 
evening (n=140, number of levodopa reports ranging from 11 to 467) and night (n=99, number of 
levodopa reports ranging from 11 to 197). 4B - Mean time spent walking per hour before (black) and 
after levodopa intake (white) on weekend days, presented separately for the morning (n=134, 
number of levodopa reports per person ranging from 11 to 170), afternoon (n=129, number of 
levodopa reports ranging from 11 to 129), evening (n=100, number of levodopa reports ranging from 
11 to 180) and night (n=61, number of levodopa reports ranging from 11 to 72). Error bars indicate 
standard error of the mean. 
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Table 1: Demographic and clinical characteristic of the study participants (n=304). 
Characteristic 
n (%) Mean±SD 
Gender Men 163 (66%) - 
Age (years) - 63.1±8.5 
Time since diagnose (years)   - 6.1±4.3 
Disease stage
1 
  
 
 
0 6 (3%) - 
1 68 (28%) - 
2 127 (53%) - 
3 34 (14%) - 
4 5 (2%) - 
5 1 (0.4%) - 
Cognitive impairment2 
  - 25.4±3.0 
Severity of motor symptoms3 
- 28±14.5 
Independency level4 
≤70 36 (15%)  - 
71-80 51 (21%)  - 
81-90 110 (46%)  - 
≥91 41 (17%)  - 
Severity of fluctuations5 
None 120 (50%) - 
Slight 42 (17%) - 
Mild 21 (9%) - 
Moderate 47 (20%) - 
Severe 11 (5%) - 
*Number of missing values differed across variables; only valid percentages are reported. 1-Disease stage: Hoehn and Yahr 
stage (0-5 point scale); 2-Cognitive impairment: Montreal Cognitive Assessment (0-30); 3- Severity of motor symptoms: sum 
of Movement Disorders Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III (0-132); 4-Independency 
level: Schwab and England scale (0-100), 5-Impact of motor fluctuations: item 4.4 from MDS-UPDRS part IV (0-4 point 
scale). 
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Table 2: Adjusted impact of the severity of motor fluctuations on post-levodopa activity (in minutes). 
  
n B ± SE β p-value 
ΔR
2 
Morning 166 
.004 ± .104 .002 .97 <.001 
Afternoon 162 .156 ± .082 .074 .06 .005 
Evening 134 .082 ± .044 .122 .07 .015 
Night 95 .124 ± .203 .044 .54 .002 
Confounders and R2 per model: 
Morning: pre-levodopa activity (p = .43), mean time spent walking (p < .001); R2 = .72. 
Afternoon: pre-levodopa activity (p < .001), mean time spent walking (p < .001); R2 = .77. 
Evening: pre-levodopa activity (p < .001); R2 = .44. 
Night: pre-levodopa activity (p = .002), mean time spent walking (p < .001), age (p=.03); R2 = .54.
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